drugset / Trial / NCT00650520
Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study is to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg bromocriptine mesylate tablets, following the administration of a 10 mg dose, under fed conditions.
Timeline
- Start
- 2007-05
- Primary completion
- 2007-07
- Completion
- 2007-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bromocriptine | Small molecule | 10 mg | — |
Indications
No indication recorded.